NO20051273L - Piperidinylforbindelser som selektivt binder integriner - Google Patents

Piperidinylforbindelser som selektivt binder integriner

Info

Publication number
NO20051273L
NO20051273L NO20051273A NO20051273A NO20051273L NO 20051273 L NO20051273 L NO 20051273L NO 20051273 A NO20051273 A NO 20051273A NO 20051273 A NO20051273 A NO 20051273A NO 20051273 L NO20051273 L NO 20051273L
Authority
NO
Norway
Prior art keywords
selectively bind
piperidinyl compounds
bind integrins
compounds
piperidinyl
Prior art date
Application number
NO20051273A
Other languages
English (en)
Other versions
NO332036B1 (no
Inventor
Bart De Corte
William A Kinney
Bruce E Maryanoff
Shyamali Ghosh
Li Liu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20051273L publication Critical patent/NO20051273L/no
Publication of NO332036B1 publication Critical patent/NO332036B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives piperidinylforbindelser med formel (I) og (II) der W, R2, Z og q er som beskrevet. Forbindelsene med formel (I) og (II) binder selektivt integrinreseptorer og egner seg derfor for behandling av integrin-medierte lidelser.
NO20051273A 2002-08-16 2005-03-11 Piperidinylforbindelser som selektivt binder integriner og sammensetninger derav NO332036B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40423902P 2002-08-16 2002-08-16
PCT/US2003/025782 WO2004020435A1 (en) 2002-08-16 2003-08-15 Piperidinyl compounds that selectively bind integrins

Publications (2)

Publication Number Publication Date
NO20051273L true NO20051273L (no) 2005-05-10
NO332036B1 NO332036B1 (no) 2012-06-04

Family

ID=31978252

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051273A NO332036B1 (no) 2002-08-16 2005-03-11 Piperidinylforbindelser som selektivt binder integriner og sammensetninger derav

Country Status (24)

Country Link
US (1) US20040077684A1 (no)
EP (1) EP1539739B1 (no)
JP (1) JP4554364B2 (no)
KR (1) KR20050031464A (no)
CN (1) CN100506815C (no)
AR (1) AR041010A1 (no)
AT (1) ATE489378T1 (no)
AU (2) AU2003259891A1 (no)
BR (1) BR0313534A (no)
CA (1) CA2496127C (no)
CR (1) CR7692A (no)
CY (1) CY1111194T1 (no)
DE (1) DE60335118D1 (no)
DK (1) DK1539739T3 (no)
ES (1) ES2355139T3 (no)
IL (1) IL166534A (no)
MX (1) MXPA05001859A (no)
NO (1) NO332036B1 (no)
PL (1) PL219749B1 (no)
PT (1) PT1539739E (no)
RU (1) RU2333210C2 (no)
SI (1) SI1539739T1 (no)
UA (1) UA83467C2 (no)
WO (1) WO2004020435A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US7351711B2 (en) 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
EP1830902A2 (en) * 2004-12-30 2007-09-12 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
EP1833512A1 (en) * 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
SI2178858T1 (sl) * 2007-08-02 2012-03-30 Recordati Ireland Ltd Nove heterociklične spojine kot mGlu antagonisti
WO2009058314A1 (en) 2007-10-30 2009-05-07 Janssen Pharmaceutica, N.V. Enantioselective process for preparing a substituted alkanoic acid
EP2730282A1 (en) * 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
SI3050878T1 (sl) 2013-09-24 2022-01-31 Fujifilm Corporation Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te
EP3512839A4 (en) 2016-09-18 2020-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. AGAINST INTERACTION OF YAP1 WITH YCT1 INHIBITORS
BR112019009245A2 (pt) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
HRP20210228T1 (hr) * 2016-11-08 2021-03-19 Bristol-Myers Squibb Company Amidi pirola kao inhibitori alfa v integrina
MA52117A (fr) * 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
BR112020018642A2 (pt) 2018-03-14 2020-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Composto da fórmula i, composição farmacêutica, método de tratamento de câncer em um sujeito em necessidade, método de eliminação de uma célula tumoral em um sujeito
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
WO2025067433A1 (zh) * 2023-09-28 2025-04-03 云合智药（苏州）生物科技有限公司 靶向整合素的化合物及其在RNAi剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (no) * 1977-06-03 1981-03-07 Pfizer
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US6211191B1 (en) * 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
CA2315232A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
AU4584199A (en) * 1998-06-29 2000-01-17 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device

Also Published As

Publication number Publication date
PL375562A1 (en) 2005-11-28
EP1539739B1 (en) 2010-11-24
AR041010A1 (es) 2005-04-27
EP1539739A1 (en) 2005-06-15
KR20050031464A (ko) 2005-04-06
BR0313534A (pt) 2005-07-12
JP2005539049A (ja) 2005-12-22
CA2496127C (en) 2012-05-29
AU2010236002B2 (en) 2012-05-03
PT1539739E (pt) 2011-01-05
AU2010236002A1 (en) 2010-11-11
NO332036B1 (no) 2012-06-04
RU2333210C2 (ru) 2008-09-10
AU2003259891A1 (en) 2004-03-19
CN1688572A (zh) 2005-10-26
UA83467C2 (uk) 2008-07-25
RU2005104115A (ru) 2005-08-27
ES2355139T3 (es) 2011-03-23
WO2004020435A1 (en) 2004-03-11
IL166534A (en) 2012-05-31
IL166534A0 (en) 2006-01-15
CN100506815C (zh) 2009-07-01
SI1539739T1 (sl) 2011-04-29
PL219749B1 (pl) 2015-07-31
MXPA05001859A (es) 2005-06-03
CY1111194T1 (el) 2015-06-11
ATE489378T1 (de) 2010-12-15
DK1539739T3 (da) 2011-03-07
CR7692A (es) 2009-01-14
DE60335118D1 (de) 2011-01-05
US20040077684A1 (en) 2004-04-22
JP4554364B2 (ja) 2010-09-29
CA2496127A1 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20051273L (no) Piperidinylforbindelser som selektivt binder integriner
NO20053647L (no) Pyrazolopyridinderivater
MXPA05001354A (es) Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
CY1113054T1 (el) Παραγωγα διαμινης
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
NO20064288L (no) Tetraazabenzo(E)azulen-derivater og angaloger derav
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
NO20050828L (no) lndol-3-svovelderivater
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
WO2004018449A8 (en) Piperidine-derivatives as pde4 inhibitors
SE0202430D0 (sv) New Compounds
ATE413388T1 (de) Muskarin antagonisten
WO2005009392A3 (en) Dihydropyrimidone inhibitors of calcium channel function
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
NO20062629L (no) Oksazolderivater av tetrackliner
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
NO20052994L (no) Nye fosforamidderivater.
NO20062710L (no) 1-N-fenyl-amino-1H-imidazolderivater og farmasoytiske sammensetninger
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees